Skip to main content
SpringerLink
Log in

General synthesis of silica-based yolk/shell hybrid nanomaterials and in vivo tumor vasculature targeting

  • Research Article
  • Published:
Nano Research Aims and scope Submit manuscript

Abstract

Multifunctional yolk/shell-structured hybrid nanomaterials have attracted increasing interest as theranostic nanoplatforms for cancer imaging and therapy. However, because of the lack of suitable surface engineering and tumor targeting strategies, previous research has focused mainly on nanostructure design and synthesis with few successful examples showing active tumor targeting after systemic administration. In this study, we report the general synthetic strategy of chelator-free zirconium-89 (89Zr)-radiolabeled, TRC105 antibody-conjugated, silica-based yolk/shell hybrid nanoparticles for in vivo tumor vasculature targeting. Three types of inorganic nanoparticles with varying morphologies and sizes were selected as the internal cores, which were encapsulated into single hollow mesoporous silica nanoshells to form the yolk/shell-structured hybrid nanoparticles. As a proof-of-concept, we demonstrated successful surface functionalization of the nanoparticles with polyethylene glycol, TRC105 antibody (specific for CD105/endoglin), and 89Zr (a positron-emitting radioisotope), and enhanced in vivo tumor vasculature-targeted positron emission tomography imaging in 4T1 murine breast tumor-bearing mice. This strategy could be applied to the synthesis of other types of yolk/shell theranostic nanoparticles for tumor-targeted imaging and drug delivery.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Ledford, H. Bankruptcy filing worries developers of nanoparticle cancer drugs. Nature 2016, 533, 304–305.

    Article  Google Scholar 

  2. Shi, J.; Kantoff, P. W.; Wooster, R.; Farokhzad, O. C. Cancer nanomedicine: Progress, challenges and opportunities. Nat. Rev. Cancer 2017, 17, 20–37.

    Article  Google Scholar 

  3. Hare, J. I.; Lammers, T.; Ashford, M. B.; Puri, S.; Storm, G.; Barry, S. T. Challenges and strategies in anti-cancer nanomedicine development: An industry perspective. Adv. Drug Deliv. Rev. 2017, 108, 25–38.

    Article  Google Scholar 

  4. Davis, M. E.; Chen, Z.; Shin, D. M. Nanoparticle therapeutics: An emerging treatment modality for cancer. Nat. Rev. Drug Discov. 2008, 7, 771–782.

    Article  Google Scholar 

  5. Chen, H. M.; Zhang, W. Z.; Zhu, G. Z.; Xie, J.; Chen, X. Y. Rethinking cancer nanotheranostics. Nat. Rev. Mater. 2017, 2, 17024.

    Article  Google Scholar 

  6. Bradbury, M. S.; Pauliah, M.; Zanzonico, P.; Wiesner, U.; Patel, 5. Intraoperative mapping of sentinel lymph node metastases using a clinically translated ultrasmall silica nanoparticle. Wiley Interdiscip. Rev. Nanomed Nanobiotechnol. 2016, 8, 535–553.

    Article  Google Scholar 

  7. Croissant, J. G.; Fatieiev, Y.; Khashab, N. M. Degradability and clearance of silicon, organosilica, silsesquioxane, silica mixed oxide, and mesoporous silica nanoparticles. Adv. Mater. 2017, 29, 1604634.

    Article  Google Scholar 

  8. Purbia, R.; Paria, S. Yolk/shell nanoparticles: Classifications, synthesis, properties, and applications. Nanoscale 2015, 7, 19789–19873.

    Article  Google Scholar 

  9. Piao, Y. Z.; Burns, A.; Kim, J.; Wiesner, U.; Hyeon, T. Designed fabrication of silica-based nanostructured particle systems for nanomedicine applications. Adv. Funct. Mater. 2008, 18, 3745–3758.

    Article  Google Scholar 

  10. Benezra, M.; Penate-Medina, O.; Zanzonico, P. B.; Schaer, D.; Ow, H.; Burns, A.; DeStanchina, E.; Longo, V.; Herz, E.; Iyer, S. et al. Multimodal silica nanoparticles are effective cancertargeted probes in a model of human melanoma. J. Clin. Invest. 2011, 121, 2768–2780.

    Article  Google Scholar 

  11. Phillips, E.; Penate-Medina, O.; Zanzonico, P. B.; Carvajal, R. D.; Mohan, P.; Ye, Y. P.; Humm, J.; Gonen, M.; Kalaigian, H.; Schoder, H. et al. Clinical translation of an ultrasmall inorganic optical-pet imaging nanoparticle probe. Sci. Transl. Med. 2014, 6, 260ra149.

    Article  Google Scholar 

  12. Chen, F.; Ma, K.; Benezra, M.; Zhang, L.; Cheal, S. M.; Phillips, E.; Yoo, B.; Pauliah, M.; Overholtzer, M.; Zanzonico, P. et al. Cancer-targeting ultrasmall silica nanoparticles for clinical translation: Physicochemical structure and biological property correlations. Chem. Mater. 2017, 29, 8766–8779.

    Article  Google Scholar 

  13. Chen, F.; Ma, K.; Zhang, L.; Madajewski, B.; Zanzonico, P.; Sequeira, S.; Gonen, M.; Wiesner, U.; Bradbury, M. S. Target-or-clear zirconium-89 labeled silica nanoparticles for enhanced cancer-directed uptake in melanoma: A comparison of radiolabeling strategies. Chem. Mater. 2017, 29, 8269–8281.

    Article  Google Scholar 

  14. Chen, F.; Zhang, X. L.; Ma, K.; Madajewski, B.; Benezra, M.; Zhang, L.; Phillips, E.; Turker, M. Z.; Gallazzi, F.; Penate-Medina, O. et al. Melanocortin-1 receptor-targeting ultrasmall silica nanoparticles for dual-modality human melanoma imaging. ACSAppl. Mater. Interfaces 2018, 10, 4379–4393.

    Article  Google Scholar 

  15. Chen, F.; Goel, S.; Valdovinos, H. F.; Luo, H. M.; Hernandez, R.; Barnhart, T. E.; Cai, W. B. In vivo integrity and biological fate of chelator-free zirconium-89-labeled mesoporous silica nanoparticles. ACS Nano 2015, 9, 7950–7959.

    Article  Google Scholar 

  16. Shaffer, T. M.; Wall, M. A.; Harmsen, S.; Longo, V. A.; Drain, C. M.; Kircher, M. F.; Grimm, J. Silica nanoparticles as substrates for chelator-free labeling of oxophilic radioisotopes. Nano Lett. 2015, 15, 864–868.

    Article  Google Scholar 

  17. Shaffer, T. M.; Harmsen, S.; Khwaja, E.; Kircher, M. F.; Drain, C. M.; Grimm, J. Stable radiolabeling of sulfur-functionalized silica nanoparticles with copper-64. Nano Lett. 2016, 16, 5601–5604.

    Article  Google Scholar 

  18. Ellison, P. A.; Chen, F.; Goel, S.; Barnhart, T. E.; Nickles, R. J.; DeJesus, O. T.; Cai, W. B. Intrinsic and stable conjugation of thiolated mesoporous silica nanoparticles with radioarsenic. ACS Appl. Mater. Interfaces 2017, 9, 6772–6781.

    Article  Google Scholar 

  19. Chen, F.; Valdovinos, H. F.; Hernandez, R.; Goel, S.; Barnhart, T. E.; Cai, W. B. Intrinsic radiolabeling of titanium-45 using mesoporous silica nanoparticles. Acta Pharmacol. Sin. 2017, 38, 907–913.

    Article  Google Scholar 

  20. Lee, J. E.; Lee, N.; Kim, T.; Kim, J.; Hyeon, T. Multifunctional mesoporous silica nanocomposite nanoparticles for theranostic applications. Acc. Chem. Res. 2011, 44, 893–902.

    Article  Google Scholar 

  21. Tang, F. Q.; Li, L. L.; Chen, D. Mesoporous silica nanoparticles: Synthesis, biocompatibility and drug delivery. Adv. Mater. 2012, 24, 1504–1534.

    Article  Google Scholar 

  22. Chen, Y.; Chen, H. R.; Zeng, D. P.; Tian, Y. B.; Chen, F.; Feng, J. W.; Shi, J. L. Core/shell structured hollow mesoporous nanocapsules: A potential platform for simultaneous cell imaging and anticancer drug delivery. ACS Nano 2010, 4, 6001–6013.

    Article  Google Scholar 

  23. Chen, F.; Hong, H.; Zhang, Y.; Valdovinos, H. F.; Shi, S. X.; Kwon, G. S.; Theuer, C. P.; Barnhart, T. E.; Cai, W. B. In vivo tumor targeting and image-guided drug delivery with antibodyconjugated, radiolabeled mesoporous silica nanoparticles. ACS Nano 2013, 7, 9027–9039.

    Article  Google Scholar 

  24. Chen, F.; Hong, H.; Goel, S.; Graves, S. A.; Orbay, H.; Ehlerding, E. B.; Shi, S. X.; Theuer, C. P.; Nickles, R. J.; Cai, W. B. In vivo tumor vasculature targeting of CuS@MSN based theranostic nanomedicine. ACS Nano 2015, 9, 3926–3934.

    Article  Google Scholar 

  25. Chen, F.; Hong, H.; Shi, S. X.; Goel, S.; Valdovinos, H. F.; Hernandez, R.; Theuer, C. P.; Barnhart, T. E.; Cai, W. B. Engineering of hollow mesoporous silica nanoparticles for remarkably enhanced tumor active targeting efficacy. Sci. Rep. 2014, 4, 5080.

    Article  Google Scholar 

  26. Shi, S. X.; Chen, F.; Cai, W. B. Biomedical applications of functionalized hollow mesoporous silica nanoparticles: Focusing on molecular imaging. Nanomedicine 2013, 8, 2027–2039.

    Article  Google Scholar 

  27. Liu, J.; Qiao, S. Z.; Budi Hartono, S.; Lu, G. Q. Monodisperse yolk-shell nanoparticles with a hierarchical porous structure for delivery vehicles and nanoreactors. Angew. Chem., Int. Ed 2010, 49, 4981–4985.

    Article  Google Scholar 

  28. Chen, D.; Li, L. L.; Tang, F. Q.; Qi, S. Facile and scalable synthesis of tailored silica "nanorattle" structures. Adv. Mater. 2009, 21, 3804–3807.

    Article  Google Scholar 

  29. Fan, W. P.; Shen, B.; Bu, W. B.; Chen, F.; Zhao, K. L.; Zhang, S. J.; Zhou, L. P.; Peng, W. J.; Xiao, Q. F.; Xing, H. Y. et al. Rattle-structured multifunctional nanotheranostics for synergetic chemo-/radiotherapy and simultaneous magnetic/luminescent dual-mode imaging. J. Am. Chem. Soc. 2013, 135, 6494–6503.

    Article  Google Scholar 

  30. Liu, J. N.; Liu, Y.; Bu, W. B.; Bu, J. W.; Sun, Y.; Du, J. L.; Shi, J. L. Ultrasensitive nanosensors based on upconversion nanoparticles for selective hypoxia imaging in vivo upon near-infrared excitation. J. Am. Chem. Soc. 2014, 136, 9701–9709.

    Article  Google Scholar 

  31. Liu, Y. Y.; Liu, Y.; Bu, W. B.; Xiao, Q. F.; Sun, Y.; Zhao, K. L.; Fan, W. P.; Liu, J. N.; Shi, J. L. Radiation-/hypoxia-induced solid tumor metastasis and regrowth inhibited by hypoxiaspecific upconversion nanoradiosensitizer. Biomaterials 2015, 49, 1–8.

    Article  Google Scholar 

  32. Chen, Y.; Chen, H. R.; Guo, L. M.; He, Q. J.; Chen, F.; Zhou, J.; Feng, J. W.; Shi, J. L. Hollow/rattle-type mesoporous nanostructures by a structural difference-based selective etching strategy. ACS Nano 2010, 4, 529–539.

    Article  Google Scholar 

  33. Zhang, Q.; Zhang, T. R.; Ge, J. P.; Yin, Y. D. Permeable silica shell through surface-protected etching. Nano Lett. 2008, 8, 2867–2871.

    Article  Google Scholar 

  34. Lin, L. S.; Song, J. B.; Yang, H. H.; Chen, X. Y. Yolk-shell nanostructures: Design, synthesis, and biomedical applications. Adv. Mater. 2018, 30, 1704639.

    Article  Google Scholar 

  35. Liu, J.; Qiao, S. Z.; Chen, J. S.; Lou, X. W.; Xing, X. R.; Lu, G. Q. Yolk/shell nanoparticles: New platforms for nanoreactors, drug delivery and lithium-ion batteries. Chem. Commun. 2011, 47, 12578–12591.

    Article  Google Scholar 

  36. Priebe, M.; Fromm, K. M. Nanorattles or yolk-shell nanoparticles—what are they, how are they made, and what are they good for? Chem.—Eur. J. 2015, 21, 3854–3874.

    Article  Google Scholar 

  37. Fang, J.; Nakamura, H.; Maeda, H. The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv. Drug Deliv. Rev. 2011, 63, 136–151.

    Article  Google Scholar 

  38. Chen, F.; Cai, W. B. Tumor vasculature targeting: A generally applicable approach for functionalized nanomaterials. Small 2014, 10, 1887–1893.

    Article  Google Scholar 

  39. Seon, B. K.; Haba, A.; Matsuno, F.; Takahashi, N.; Tsujie, M.; She, X. W.; Harada, N.; Uneda, S.; Tsujie, T.; Toi, H. et al. Endoglin-targeted cancer therapy. Curr. Drug Deliv. 2011, 8, 135–143.

    Article  Google Scholar 

  40. Rosen, L. S.; Hurwitz, H. I.; Wong, M. K.; Goldman, J.; Mendelson, D. S.; Figg, W. D.; Spencer, S.; Adams, B. J.; Alvarez, D.; Seon, B. K. et al. A phase I first-in-human study of TRC105 (anti-endoglin antibody) in patients with advanced cancer. Clin. Cancer Res. 2012, 18, 4820–4829.

    Article  Google Scholar 

  41. Hong, H.; Yang, K.; Zhang, Y.; Engle, J. W.; Feng, L. Z.; Yang, Y.; Nayak, T. R.; Goel, S.; Bean, J.; Theuer, C. P. et al. In vivo targeting and imaging of tumor vasculature with radiolabeled, antibody-conjugated nanographene. ACS Nano 2012, 6, 2361–2370.

    Article  Google Scholar 

  42. Chen, F.; Nayak, T. R.; Goel, S.; Valdovinos, H. F.; Hong, H.; Theuer, C. P.; Barnhart, T. E.; Cai, W. B. In vivo tumor vasculature targeted PET/NIRF imaging with TRC105(fab)-conjugated, dual-labeled mesoporous silica nanoparticles. Mol. Pharmaceutics 2014, 11, 4007–4014.

    Article  Google Scholar 

  43. Goel, S.; Chen, F.; Luan, S. J.; Valdovinos, H. F.; Shi, S. X.; Graves, S. A.; Ai, F. R.; Barnhart, T. E.; Theuer, C. P.; Cai, W. B. Engineering intrinsically zirconium-89 radiolabeled self-destructing mesoporous silica nanostructures for in vivo biodistribution and tumor targeting studies. Adv. Sci. 2016, 3, 1600122.

    Article  Google Scholar 

  44. Zhou, J.; Liu, Z.; Li, F. Y. Upconversion nanophosphors for small-animal imaging. Chem. Soc. Rev. 2012, 41, 1323–1349.

    Article  Google Scholar 

  45. Haase, M.; Schäfer, H. Upconverting nanoparticles. Angew. Chem., Int. Ed. 2011, 50, 5808–5829.

    Article  Google Scholar 

  46. Ju, Q.; Tu, D. T.; Liu, Y. S.; Li, R. F.; Zhu, H. M.; Chen, J. C.; Chen, Z.; Huang, M. D.; Chen, X. Y. Amine-functionalized lanthanide-doped KGdF4 nanocrystals as potential optical/magnetic multimodal bioprobes. J. Am. Chem. Soc. 2012, 134, 1323–1330.

    Article  Google Scholar 

  47. Wu, S. W.; Han, G.; Milliron, D. J.; Aloni, S.; Altoe, V.; Talapin, D. V.; Cohen, B. E.; Schuck, P. J. Non-blinking and photostable upconverted luminescence from single lanthanide-doped nanocrystals. Proc. Natl. Acad. Sci. USA 2009, 106, 10917–10921.

    Article  Google Scholar 

  48. Cheng, L.; Wang, C.; Liu, Z. Upconversion nanoparticles and their composite nanostructures for biomedical imaging and cancer therapy. Nanoscale 2013, 5, 23–37.

    Article  Google Scholar 

  49. Park, Y. I.; Kim, J. H.; Lee, K. T.; Jeon, K. S.; Bin Na, H.; Yu, J. H.; Kim, H. M.; Lee, N.; Choi, S. H.; Baik, S. I. et al. Nonblinking and nonbleaching upconverting nanoparticles as an optical imaging nanoprobe and T1 magnetic resonance imaging contrast agent. Adv. Mater. 2009, 21, 4467–4471.

    Article  Google Scholar 

  50. Chatterjee, D. K.; Rufaihah, A. J.; Zhang, Y. Upconversion fluorescence imaging of cells and small animals using lanthanide doped nanocrystals. Biomaterials 2008, 29, 937–943.

    Article  Google Scholar 

  51. Nam, S. H.; Bae, Y. M.; Park, Y. I.; Kim, J. H.; Kim, H. M.; Choi, J. S.; Lee, K. T.; Hyeon, T.; Suh, Y. D. Long-term real-time tracking of lanthanide ion doped upconverting nanoparticles in living cells. Angew. Chem., Int. Ed 2011, 50, 6093–6097.

    Article  Google Scholar 

  52. Xiong, L. Q.; Chen, Z. G.; Tian, Q. W.; Cao, T. Y.; Xu, C. J.; Li, F. Y High contrast upconversion luminescence targeted imaging in vivo using peptide-labeled nanophosphors. Anal. Chem. 2009, 81, 8687–8694.

    Article  Google Scholar 

  53. Chen, F.; Bu, W. B.; Zhang, S. J.; Liu, J. N.; Fan, W. P.; Zhou, L. P.; Peng, W. J.; Shi, J. L. Gd3+-ion-doped upconversion nanoprobes: Relaxivity mechanism probing and sensitivity optimization. Adv. Funct. Mater. 2013, 23, 298–307.

    Article  Google Scholar 

  54. Chen, F.; Bu, W. B.; Zhang, S. J.; Liu, X. H.; Liu, J. N.; Xing, H. Y.; Xiao, Q. F.; Zhou, L. P.; Peng, W. J.; Wang, L. Z. et al. Positive and negative lattice shielding effects co-existing in Gd (III) ion doped bifunctional upconversion nanoprobes. Adv. Funct. Mater. 2011, 21, 4285–4294.

    Article  Google Scholar 

  55. Chen, F.; Bu, W. B.; Chen, Y.; Fan, Y. C.; He, Q. J.; Zhu, M.; Liu, X. H.; Zhou, L. P.; Zhang, S. J.; Peng, W. J. et al. A sub-50-nm monosized superparamagnetic Fe3O4@SiO2 T2-weighted MRI contrast agent: Highly reproducible synthesis of uniform single-loaded core-shell nanostructures. Chem. — Asian J 2009, 4, 1809–1816.

    Article  Google Scholar 

  56. Taylor, K. M. L.; Kim, J. S.; Rieter, W. J.; An, H. Y.; Lin, W. L.; Lin, W. B. Mesoporous silica nanospheres as highly efficient MRI contrast agents. J. Am. Chem. Soc. 2008, 130, 2154–2155.

    Article  Google Scholar 

  57. Fang, X. L.; Chen, C.; Liu, Z. H.; Liu, P. X.; Zheng, N. F. A cationic surfactant assisted selective etching strategy to hollow mesoporous silica spheres. Nanoscale 2011, 3, 1632–1639.

    Article  Google Scholar 

  58. Chen, F.; Ellison, P. A.; Lewis, C. M.; Hong, H.; Zhang, Y.; Shi, S. X.; Hernandez, R.; Meyerand, M. E.; Barnhart, T. E.; Cai, W. B. Chelator-free synthesis of a dual-modality PET/MRI agent. Angew. Chem, Int. Ed 2013, 52, 13319–13323.

    Article  Google Scholar 

  59. Zhuravlev, L. T. The surface chemistry of amorphous silica. Zhuravlev model. Colloids Surf. A 2000, 173, 1–38.

    Article  Google Scholar 

  60. Fonsatti, E.; Nicolay, H. J.; Altomonte, M.; Covre, A.; Maio, M. Targeting cancer vasculature via endoglin/CD105: A novel antibody-based diagnostic and therapeutic strategy in solid tumours. Cardiovasc. Res. 2010, 86, 12–19. 15

    Article  Google Scholar 

  61. Tian, B.; Wang, Q. H.; Su, Q. Q.; Feng, W.; Li, F. Y. In vivo biodistribution and toxicity assessment of triplet-triplet annihilation-based upconversion nanocapsules. Biomaterials 2017, 112, 10–19.

    Article  Google Scholar 

  62. Sun, Y.; Feng, W.; Yang, P. Y.; Huang, C. H.; Li, F. Y. The biosafety of lanthanide upconversion nanomaterials. Chem. Soc. Rev. 2015, 44, 1509–1525.

    Article  Google Scholar 

  63. Feng, Q. Y.; Liu, Y. P.; Huang, J.; Chen, K.; Huang, J. X.; Xiao, K. Uptake, distribution, clearance, and toxicity of iron oxide nanoparticles with different sizes and coatings. Sci. Rep. 2018, 8, 2082.

    Article  Google Scholar 

  64. Singh, N.; Jenkins, G. J. S.; Asadi, R.; Doak, S. H. Potential toxicity of superparamagnetic iron oxide nanoparticles (SPION). Nano Rev. 2010, 1, 5358.

    Article  Google Scholar 

  65. Tsoi, K. M.; Dai, Q.; Alman, B. A.; Chan, W. C. W. Are quantum dots toxic? Exploring the discrepancy between cell culture and animal studies. Acc. Chem. Res. 2013, 46, 662–671.

    Google Scholar 

  66. Ye, L.; Yong, K. T.; Liu, L. W.; Roy, I.; Hu, R.; Zhu, J.; Cai, H. X.; Law, W. C.; Liu, J. W.; Wang, K. et al. A pilot study in non-human primates shows no adverse response to intravenous injection of quantum dots. Nat. Nanotechnol. 2012, 7, 453–458.

    Article  Google Scholar 

  67. Zhang, Y.; Hong, H.; Severin, G. W.; Engle, J. W.; Yang, Y.; Goel, S.; Nathanson, A. J.; Liu, G.; Nickles, R. J.; Leigh, B. R. et al. ImmunoPET and near-infrared fluorescence imaging of CD105 expression using a monoclonal antibody dual-labeled with 89Zr and IRDye 800CW. Am. J. Transl. Res. 2012, 4, 333–346.

    Google Scholar 

  68. Zhang, Y.; Hong, H.; Orbay, H.; Valdovinos, H. F.; Nayak, T. R.; Theuer, C. P.; Barnhart, T. E.; Cai, W. B. PET imaging of CD105/endoglin expression with a 61/64Cu-labeled Fab antibody fragment. Eur. J. Nucl. Med. Mol. Imaging 2013, 40, 759–767.

    Article  Google Scholar 

  69. Zhang, Y.; Hong, H.; Engle, J. W.; Yang, Y.; Barnhart, T. E.; Cai, W. Positron emission tomography and near-infrared fluorescence imaging of vascular endothelial growth factor with dual-labeled bevacizumab. Am. J. Nucl. Med. Mol. Imaging 2012, 2, 1–13.

    Google Scholar 

  70. Shi, S. X.; Yang, K.; Hong, H.; Valdovinos, H. F.; Nayak, T. R.; Zhang, Y.; Theuer, C. P.; Barnhart, T. E.; Liu, Z.; Cai, W. B. Tumor vasculature targeting and imaging in living mice with reduced graphene oxide. Biomaterials 2013, 34, 3002–3009.

    Article  Google Scholar 

  71. Hong, H.; Zhang, Y.; Severin, G. W.; Yang, Y.; Engle, J. W.; Niu, G.; Nickles, R. J.; Chen, X. Y.; Leigh, B. R.; Barnhart, T. E. et al. Multimodality imaging of breast cancer experimental lung metastasis with bioluminescence and a monoclonal antibody dual-labeled with 89Zr and IRDye 800CW. Mol. Pharmaceutics 2012, 9, 2339–2349.

    Article  Google Scholar 

Download references

Acknowledgements

This work is supported, in part, by the University of Wisconsin-Madison, the National Institutes of Health (P30CA014520 and NIBIB/NCI 1R01CA169365), the National Natural Science Foundation of China (No. 81630049), and the American Cancer Society (No. 125246-RSG-13-099-01-CCE).

Author information

Authors and Affiliations

  1. Department of Radiology, University of Wisconsin-Madison, Madison, WI, 53705, USA

    Feng Chen & Weibo Cai

  2. Materials Science Program, University of Wisconsin-Madison, Madison, WI, 53705, USA

    Shreya Goel, Sixiang Shi & Weibo Cai

  3. Department of Medical Physics, University of Wisconsin-Madison, Madison, WI, 53705, USA

    Todd E. Barnhart & Weibo Cai

  4. Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China

    Xiaoli Lan

  5. University of Wisconsin Carbone Cancer Center, Madison, WI, 53705, USA

    Weibo Cai

Authors
  1. Feng Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shreya Goel
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sixiang Shi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Todd E. Barnhart
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Xiaoli Lan
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Weibo Cai
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Xiaoli Lan or Weibo Cai.

Electronic supplementary material

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Chen, F., Goel, S., Shi, S. et al. General synthesis of silica-based yolk/shell hybrid nanomaterials and in vivo tumor vasculature targeting. Nano Res. 11, 4890–4904 (2018). https://doi.org/10.1007/s12274-018-2078-9

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12274-018-2078-9

Keywords

Search

Navigation